At the archive date, WEST PHARMACEUTICAL SERVICES INC was expected to release its Q3 2026 10-Q filing on October 21, 2026, before market open. Last quarter: West Pharmaceutical Services (WST) delivered strong Q2 FY2026 results with revenue up 13.8% YoY to $872.3M and net income up 16.8% to $154.0M, driven by robust Proprietary Products demand (HVP components and delivery devices tied to GLP-1 and Biologics growth), though West Vantage segment profitability was pressured by a May 2026 cybersecurity incident.
EPS Estimate
$2.21
Revenue Estimate
$833.81M
Analyst consensus captured from Finnhub and Financial Modeling Prep. This archived preview is no longer updated with later results; see the WST page for retained reports.
Drawn from management commentary in the Q2 2026 10-Q:
Proprietary Products net sales increased 16.6% (15.5% organic) to $722.6M in Q2 FY2026, with HVP components sales up 18.4% (ex-FX) driven by continued strong customer demand for Biologics and GLP-1 products, and HVP delivery devices up 29.2% (ex-FX) driven by demand for self-injection devices, particularly SmartDose 3.5mL ahead of its July 2026 divestiture to AbbVie.
West Vantage net sales grew only 2.0% (0.8% organic) to $149.7M, with revenue growth negatively impacted by approximately $7 million from production downtime associated with the Company's May 2026 cyber incident; segment operating profit fell 27.5% YoY to $12.9M and gross margin contracted 3.3 percentage points to 14.2%.
Consolidated gross profit margin rose 2.0 percentage points to 37.7% in Q2 FY2026, with Proprietary Products gross margin up 2.5 points to 42.6% due to favorable sales mix of HVP components (including GLP-1 products) and price increases, partially offset by inflationary pressures and plant costs.
Revenue
$872.3M
+13.80% YoY
EPS (Diluted)
$2.15
+18.13% YoY
Gross Margin
37.7%
+2.0 pts YoY
Operating Income
$179.1M
+16.53% YoY
Add WST to your watchlist to keep its archived reports easy to find. New filing alerts are no longer sent.